1. Home
  2. TENB vs ZYME Comparison

TENB vs ZYME Comparison

Compare TENB & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tenable Holdings Inc.

TENB

Tenable Holdings Inc.

HOLD

Current Price

$17.92

Market Cap

2.3B

Sector

Technology

ML Signal

HOLD

Logo Zymeworks Inc.

ZYME

Zymeworks Inc.

HOLD

Current Price

$26.81

Market Cap

1.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TENB
ZYME
Founded
2002
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.3B
1.9B
IPO Year
2018
2022

Fundamental Metrics

Financial Performance
Metric
TENB
ZYME
Price
$17.92
$26.81
Analyst Decision
Buy
Strong Buy
Analyst Count
18
11
Target Price
$32.76
$38.90
AVG Volume (30 Days)
2.4M
560.0K
Earning Date
04-28-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
3.23
33.33
EPS
N/A
N/A
Revenue
$999,405,000.00
$105,965,000.00
Revenue This Year
$9.37
$162.82
Revenue Next Year
$7.04
N/A
P/E Ratio
N/A
N/A
Revenue Growth
11.04
38.87
52 Week Low
$15.85
$9.03
52 Week High
$35.69
$28.49

Technical Indicators

Market Signals
Indicator
TENB
ZYME
Relative Strength Index (RSI) 41.27 66.40
Support Level $17.28 $22.28
Resistance Level $21.25 $27.35
Average True Range (ATR) 1.00 0.93
MACD 0.01 0.25
Stochastic Oscillator 42.12 97.68

Price Performance

Historical Comparison
TENB
ZYME

About TENB Tenable Holdings Inc.

Founded in 2002, Tenable is a cybersecurity company that began providing vulnerability management solutions under its Nessus software. In recent years, Tenable has expanded its portfolio to provide a broader range of exposure management modules. Solutions include cloud security and compliance, active directory management, operational technology security and advanced vulnerability analytics. The Maryland-based company went public in 2018.

About ZYME Zymeworks Inc.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Share on Social Networks: